Oral ofloxacin for the treatment of acute bacterial pneumonia: Use of a nontraditional protocol to compare experimental therapy with “usual care” in a multicenter clinical trial

https://doi.org/10.1016/0002-9343(91)90125-HGet rights and content

Abstract

purpose: This multicenter study was designed to compare an exclusively oral regimen with “usual care” in patients hospitalized with acute bacterial pneumonia.

patients and methods: One hundred fortyseven patients were enrolled. All patients presented with a clinical picture consistent with pneumonia: (1) clinical symptoms of a lower respiratory tract infection, such as chest pain, cough, and production of purulent sputum; (2) roentgenographic infiltrate compatible with acute infection; and (3) Gram's stain of purulent sputum or other appropriate bronchopulmonary specimen containing gram-negative organisms, staphylococci, or pneumococci. All patients required hospitalization. The design was a parallel-group, open-label study with randomization in blocks of four. Ofloxacin, a new fluoroquinolone antimicrobial agent, was administered orally or by nasogastric tube, 400 mg every 12 hours. This was compared with the individual investigator's best selection of therapy that was administered parenterally, at least initially.

results: One hundred thirty-three patients were evaluable after exclusions for deviation from protocol, early death due to unrelated causes, incorrect diagnosis, or early adverse drug reactions. All 69 patients treated with ofloxacin and 61 of 64 control patients had favorable clinical and microbiologic responses. There were no statistically significant differences between the groups in terms of demographics, therapeutic outcome, and duration of therapy. There were few side effects overall and rates were similar for the two groups.

conclusions: An exclusively oral regimen, in this case ofloxacin, may be substituted for parenteral therapy in selected patients with pneumonia. This might significantly reduce costs and risks to the patient.

References (24)

  • VT Andriole

    Clinical overview of the newer 4-quinolone antibacterial agents

  • I Phillips et al.

    In vitro properties of the quinolones

  • T Bergan

    Pharmacokinetics of fluoroquinolones

  • F Bellido et al.

    Laboratory survey of fluoroquinolone activity

    Rev Infect Dis

    (1989)
  • H Lode et al.

    Pharmacokinetics of ofloxacin after parenteral and oral administration

    Antimicrob Agents Chemother

    (1987)
  • S Flor

    Pharmacokinetics of ofloxacin: an overview

    Am J Med

    (1989)
  • J Symonds et al.

    Penetration of ofloxacin into bronchial secretions

    Drugs

    (1987)
  • WJA Wijnands et al.

    The penetration of ofloxacin into lung tissue

    J Antimicrob Chemother

    (1988)
  • J Symonds et al.

    The penetration of ofloxacin into bronchial secretions

    J Antimicrob Chemother

    (1988)
  • JH Yuk et al.

    Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding

    Antimicrob Agents Chemother

    (1989)
  • National Committee for Clinical Laboratory Standards

    Methods for dilution antimicrobial susceptibility tests for bacteria that grow anaerobically

  • National Committee for Clinical Laboratory Standards

    Performance standard for antimicrobial disk susceptibility tests

  • Cited by (47)

    • Quinolones

      2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
    • Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: A randomized controlled trial

      2001, American Journal of Medicine
      Citation Excerpt :

      Our study supports the growing evidence that an oral course of antibiotics is safe and effective in patients currently admitted to the hospital who do not have severe pneumonia; it also suggests that these patients could be treated safely as outpatients or admitted for a short stay until a favorable course is observed. In patients with severe pneumonia, our results support the findings of previous retrospective (22), nonrandomized (23,24), or noncontrolled (25–28) studies and studies that had less well-defined inclusion and severity criteria (29–32). Those studies reported that treatment can be switched to oral therapy in patients who do well clinically.

    View all citing articles on Scopus

    This study was supported by a grant from Ortho Pharmaceutical Corporation, Route 202, Raritan, New Jersey.

    View full text